Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.

A nanoparticle (NP)-peptide conjugate provides efficient steric hindrance/blockage of cellular membrane potassium (K.sup.+) channels to mediate depolarization of cellular membrane potential.

A nanoparticle (NP)-peptide conjugate provides efficient steric hindrance/blockage of cellular membrane potassium (K.sup.+) channels to mediate depolarization of cellular membrane potential.

Modified metal-organic framework (MOFs) are described that have surfaces with enhanced ability to coordinatively bond to or electrostatically interact with therapeutic agents, such as nucleic acids and small molecules and proteins with phosphate or carboxylate groups. Methods of providing the modified MOFs are described that include replacing strongly coordinating metal oxo cluster capping groups with weakly coordinating capping groups and/or incorporating organic bridging ligands with electron-withdrawing groups. MOFs with surface attached therapeutic agents (e.g., immunotherapeutic agents) prepared from the modified MOFs are also described, along with methods of using the MOFs as to treat cancer, e.g., via radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator. Thus, the described methods can involve cancer immunotherapy and in situ cancer vaccination.

Modified metal-organic framework (MOFs) are described that have surfaces with enhanced ability to coordinatively bond to or electrostatically interact with therapeutic agents, such as nucleic acids and small molecules and proteins with phosphate or carboxylate groups. Methods of providing the modified MOFs are described that include replacing strongly coordinating metal oxo cluster capping groups with weakly coordinating capping groups and/or incorporating organic bridging ligands with electron-withdrawing groups. MOFs with surface attached therapeutic agents (e.g., immunotherapeutic agents) prepared from the modified MOFs are also described, along with methods of using the MOFs as to treat cancer, e.g., via radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator. Thus, the described methods can involve cancer immunotherapy and in situ cancer vaccination.

A method of using a boron cluster as a transmembrane carrier to transport a bioactive molecule across a membrane of a cell or a vesicle. The method includes providing a boron cluster having at least one hydrogen atom and/or at least one halogen atom, providing a bioactive molecule which is cationic, zwitterionic or not charged, so that the bioactive molecule is not negatively charged, and using the boron cluster as a transmembrane carrier to transport the bioactive molecule across the membrane of the cell or the vesicle.

A method of using a boron cluster as a transmembrane carrier to transport a bioactive molecule across a membrane of a cell or a vesicle. The method includes providing a boron cluster having at least one hydrogen atom and/or at least one halogen atom, providing a bioactive molecule which is cationic, zwitterionic or not charged, so that the bioactive molecule is not negatively charged, and using the boron cluster as a transmembrane carrier to transport the bioactive molecule across the membrane of the cell or the vesicle.

The invention relates to a composition comprising: i) one or more LDH-active anion materials comprising an LDH matrix intercalated with one or more active anions, and ii) a modifier system comprising a) one or more surfactants, in combination with b) one or more compounds having the generic formula MA, where M comprises one or more positively charged ions and A comprises one or more negatively charged counter ions.

The invention relates to a composition comprising: i) one or more LDH-active anion materials comprising an LDH matrix intercalated with one or more active anions, and ii) a modifier system comprising a) one or more surfactants, in combination with b) one or more compounds having the generic formula MA, where M comprises one or more positively charged ions and A comprises one or more negatively charged counter ions.

An iron/shikonin nano-composite and a use thereof, and a method for preparing the same by supermolecular self-assembly, belonging to the technical field of functional materials. The composite consists of shikonin and ferric ions, wherein shikonin is coordinated with the ferric ions, and the hydroxyl and carbonyl groups in shikonin are coordinated with the ferric irons to form a complex, which is then assembled by π-π stacking and hydrophobic interactions to form a nano-composite which exhibits glutathione response. The composite is obtained by the following steps: adding an aqueous solution of a ferric salt and an organic solvent solution of shikonin in sequence into water while stirring at ambient temperature, continuously stirring at ambient temperature, and centrifuging the resulting mixture to purify, thereby obtaining an iron/shikonin nano-composite in the resulting solution.